news
£12 million given to Sheffield Biomedical Research Centre
The UK’s Sheffield Biomedical Research Centre has been awarded £12 million to help accelerate R&D of vaccines and treat conditions like HIV.
List view / Grid view
haemophilia
article
Summer 2022 haemophilia trial update
Results from several haemophilia trials have been presented at the International Society on Thrombosis and Haemostasis (ISTH) Annual Congress 2022, here EPR summarises some of the key developments.
news
EMA’s human medicines committee (CHMP) May 2022 meeting highlights
The latest meeting saw EMA’s human medicines committee (CHMP) recommend the approval of nine new medicines, refuse two biosimilar medications and recommend extensions of therapeutic indication for six medicines.
article
Challenges in downstream purification of advanced therapies
John Liddell, Chief Technologist at the Centre for Process Innovation (CPI), writes about the challenges associated with gene therapy products, which constitute a major portion of the overall cell and gene therapy market.
article
Five marketing strategies for novel therapeutics
Long before the advent of Coronavirus, next-generation therapies were making headlines, but the successful development of COVID-19 vaccines, including mRNA vaccines, has now shone a spotlight on next-generation therapies. This offers a boost to the long-term growth projections for the advanced therapy medicinal products (ATMPs) sector. But although ATMPs hold…
article
Curative cell and gene therapies and healthcare system disruption
In this article, experts from Charles River Associates discuss how the introduction of cell and gene therapies will impact upon various aspects of the healthcare system, from provision of care to delivery and supply, and pricing and market access.
article
Plasma-derived therapies require a mastery of advanced bioproduction techniques
Plasma-derived therapies and medicines provide life-changing treatments for patients around the world who suffer from serious, and often rare, diseases that affect the immune system or result from non-functioning proteins in blood plasma. Carole Resman, Executive Vice President Production at LFB, describes the complex and highly regulated manufacturing process of…
news
Concizumab haemophilia trials paused over safety concerns
The occurrence of non-fatal thrombotic events in Phase III study participants has called into question the safety of concizumab.
news
Sanofi to acquire haemophilia specialists Bioverativ for $11.6bn
Sanofi and Bioverativ Inc., have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ...
news
Microcapsules to enhance the efficiency of genome-editing
Researchers have found that polymer and hybrid silica-coated microcapsules are efficient in genome-editing...
article
Shire on Haemophilia: How to treat a bleeding disorder
We caught up with Naghmana Bajwa, MD, Global Medical Affairs Haematology Lead at Shire to find out the latest in haemophilia disease research...
news
UCL Technology Fund invests £1m in gene therapy company, Freeline
20 June 2016 | By Victoria White, Digital Content Producer
Freeline is developing and commercialising gene therapies for bleeding and other life threatening or debilitating disorders...
news
EC approves Alprolix for the treatment of haemophilia B
13 May 2016 | By Victoria White, Digital Content Producer
The European Commission has approved Alprolix (rFIXFc) for the treatment of haemophilia B and maintained its orphan designation...
news
Biogen announces plans to spin off its haemophilia business
3 May 2016 | By Victoria White, Digital Content Producer
The new company, to be named at a later date, will focus on the discovery and development of therapies for the treatment of haemophilia...
news
Battle set for the European haemophilia B treatment market, says GlobalData
23 March 2016 | By Victoria White
CSL Behring’s Idelvion and Sobi/Biogen’s Alprolix will compete intensely for a share of the haemophilia B market following their expected European approvals...
